Warburg To Buy Minority Stake In Medical Devices Major Meril For $210 Mn

Leading global growth investor Warburg Pincus has agreed to pick up a minority stake for USD 210 million (about Rs 1,575 crore) in Micro Life Sciences, the parent firm of the Meril Group, which is the largest medical devices firm in the country.

Warburg said the transaction, awaiting CCI approval, will be carried out through its affiliate South Elm Investments.

Founded by the Bilakhia family, Meril is a fast-growing medical devices firm that designs, manufactures and distributes clinically relevant and state-of-the-art medical devices.

With R&D facilities, manufacturing capability, distribution reach, Meril has market leading position across several categories.

Narendra Ostawal of Warburg Pincus India said he is excited by Meril's compelling growth story and believes it stands to benefit from the secular tailwinds of healthcare in the country.

Sanjeev Bhatt of Meril said this investment establishes high degree of credibility to the domestic medical devices in the global landscape and will help them deepen their international presence, attract global talent, and scale up clinical research efforts.

Meril offers a diversified product portfolio with over 100 technologies in five therapy areas cardiovascular including structural heart devices, orthopedic implants, endo-surgery, surgical robotics and in-vitro diagnostics. It employs over 4,000 employees and has business in over 100 countries and has subsidiaries in the US, Germany, Brazil, Russia, South Africa, Bangladesh, Turkey, China and Japan.

Warburg has over USD 73 billion in private equity assets under management across a portfolio of over 235 companies. Since its founding in 1966 in New York, Warburg has raised 20 private equity funds and two real estate funds, which have invested over USD 100 billion in over 1,000 companies across 40 countries.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor